SCHEMBL3405174

SCHEMBL3405174

CCN(C(=O)c1ccc(S(N)(=O)=O)cc1)c1ccc2nc(S)sc2n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.35
KDM4E B2RXH2 2/20 0.35
KMT2A Q03164 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CA2 P00918 10/20 0.34
CA1 P00915 7/20 0.34
CA12 O43570 5/20 0.34
CA9 Q16790 4/20 0.34
ENPP3 O14638 1/20 0.34
RAB9A P51151 2/20 0.34
NPC1 O15118 1/20 0.34
MAPT P10636 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
CA6 P23280 3/20 0.33
CA7 P43166 3/20 0.33
CA13 Q8N1Q1 2/20 0.33
POLB P06746 1/20 0.33
CA3 P07451 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3403902 0.89 CA2 (0.34) GAAKDM4ECA2CA1CA12
SCHEMBL3406370 0.86 MAPT (0.37) KDM4ECA2CA1CA12CA9
SCHEMBL3408418 0.85 MAPK14 (0.36) KMT2AALDH1A1RAB9ANPC1
SCHEMBL3408965 0.85 CA2 (0.41) KMT2AALDH1A1HSD17B10CA2CA1
SCHEMBL3406389 0.85 CA1 (0.44) KDM4EKMT2AALDH1A1CA2CA1
SCHEMBL3404000 0.84 CA2 (0.39) GAAKMT2ACA2CA1CA12
SCHEMBL3406734 0.84 CA2 (0.35) KDM4ECA2CA1CA12CA9
SCHEMBL3408849 0.83 MLYCD (0.40) KDM4EKMT2AALDH1A1HSD17B10RAB9A
SCHEMBL3405142 0.82 MLYCD (0.43) KDM4EKMT2AALDH1A1NPC1MAPT
SCHEMBL3403912 0.82 MLYCD (0.40) KDM4EALDH1A1HSD17B10NPSR1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1370260-B1 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI PHARMACEUTICAL CO LTD (JP) 2010-11-24 EP claimed
US-20040092503-A1 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2004-05-13 US claimed
EP-1370260-A2 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-12-17 EP claimed
WO-2002066035-A2 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-08-29 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092503-A1 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators ME1, ME3, ME2 GAA 241/4885KDM4E 675/4885KMT2A 1536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.